Search the Newsreel

Corcept Therapeutics (CORT) Stock Analysis: Unveiling an 18% Potential Upside amid Robust Revenue Growth

Confidence Petroleum India Share Price Target 2027 to 2030: Analy

Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to form a leading CNS-focused biopharmaceutical company. This tax-free merger of equals anticipates $125 million in annual cost synergies within the first year and will create a combined portfolio of 11 medicines across addiction, ADHD, depression, and …

Occidental Petroleum stock holds steady as analysts see upside and oil stays elevated

Occidental Petroleum (OXY) stock is trading in the high-$50s, with analysts forecasting a double-digit upside due to elevated oil prices and strong sector profits. The company's financials are robust, with the energy sector showing significant profit growth year-over-year. Technical indicators suggest a "Buy" signal, …

Citizens reiterates Allogene stock rating on trial progress

Citizens reiterated a Market Outperform rating on Allogene Therapeutics Inc. (NASDAQ:ALLO), maintaining a $6.00 price target. The firm's analysis is based on discounted EPS and revenue multiples, with the company's ALPHA3 trial on track for an interim readout in mid-2027. Allogene reported strong second-quarter …

Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO

Chase Investment Counsel Corp has acquired a new stake of 26,000 shares in Halozyme Therapeutics, valued at approximately $2.0 million. This comes as institutional investors now collectively own 97.79% of the company. Despite insider selling activity, analyst sentiment remains largely positive with a "Moderate …

Malabar India Fund sells 2.12% stake in Neuland Laboratories

SFC Energy AG : Deutsche Bank reaffirms its Buy rating

Deutsche Bank has reaffirmed its "Buy" rating for SFC Energy AG, maintaining a target price of EUR 26. This decision comes as other analysts, including Warburg Research and Berenberg, also reiterated their positive outlooks for the company, with Berenberg even raising its target price …

Abeona Therapeutics (ABEO) Q2 Revenue Misses Estimates; Market Pricing Reflects Growth Uncertainty

Flputnam Investment Management Co. Invests $19.93 Million in Vertex Pharmaceuticals Incorporated $VRTX

Flputnam Investment Management Co. has acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), purchasing 40,116 shares valued at approximately $19.93 million during the second quarter. Other institutional investors have also adjusted their holdings in the pharmaceutical company. Analyst ratings for VRTX are generally …

Global Retirement Partners LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Global Retirement Partners LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, purchasing 3,925 shares valued at approximately $1,950,000. Several other institutional investors also adjusted their holdings in the pharmaceutical company. Vertex Pharmaceuticals has a market capitalization of $128.36 …

How Investors May Respond To NESR’s Strong Q2 Results And New Kuwait Technology-Driven Contracts

Neuren Pharmaceuticals (ASX:NEU) Shares in Focus as DAYBUE Growth Supports Higher Royalty Outlook

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Phathom Pharmaceuticals (NASDAQ:PHAT) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $22.86, significantly above its current trading price of $9.58. Despite some analysts lowering price targets, most maintain buy ratings, while one firm reaffirmed a …

Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN

Focus Partners Advisor Solutions LLC recently invested $1.35 million in Regeneron Pharmaceuticals, acquiring 2,165 shares during the second quarter. Regeneron reported strong quarterly results, beating analyst estimates with EPS of $14.29 and revenue of $4.29 billion, marking a 16.7% year-over-year increase. Despite potential legal …

International Petroleum Corporation Announces Results of Normal Course Issuer Bid

International Petroleum Corporation International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 205,334 IPC common shares (ISIN: CA46016U1084) during the period of August 10 to 14, 2026 under IPC's previously announced normal …

Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD

Empowered Funds LLC has made a new investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), acquiring 48,982 shares valued at approximately $1.09 million. This comes as institutional investors hold 96.71% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target …

Mirum Pharmaceuticals (MIRM) Losses Put Its Valuation Narrative Back In Focus

Mirum Pharmaceuticals (MIRM) reported wider net losses in Q2 and H1 2026, yet its share price has seen significant gains, up 28.91% year-to-date and 50.93% over one year. The company is currently trading at approximately $100, which analysts suggest is 30.2% undervalued with a …

239,800 Shares in Keurig Dr Pepper, Inc $KDP Purchased by Alberta Investment Management Corp

Alberta Investment Management Corp recently acquired a new stake of 239,800 shares in Keurig Dr Pepper, Inc. (NASDAQ:KDP), valued at approximately $7.85 million. This purchase is part of broader institutional investment activity, with several other hedge funds also adjusting their positions in KDP. Analyst …

AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

AMG National Trust Bank has made a new $1.22 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by purchasing 1,956 shares. This investment comes amidst various other hedge funds adjusting their positions in the biopharmaceutical company, which recently reported strong quarterly earnings, beating analyst estimates, …

113,200 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Alberta Investment Management Corp

Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA

Assenagon Asset Management S.A. significantly reduced its stake in Protara Therapeutics (NASDAQ:TARA) by 89.4% in the second quarter, selling 507,667 shares and retaining 59,954 shares valued at $229,000. Despite this, other institutional investors like Geode Capital Management increased their positions, with overall institutional ownership …

Kotak's Mid-Cap Model Portfolio: Eureka Forbes, ICICI Pru Life Lead With Highest Upside — Check Target Prices

Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE

2,486,038 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AIGH Capital Management LLC

AIGH Capital Management LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,486,038 shares valued at approximately $26.7 million in the second quarter, making it their 9th largest holding. Other institutional investors like Norges Bank and Bank of New York Mellon Corp …

SENORES PHARMACEUTICALS L Share Price: 52-Week High Analysis

TSX:MDNA Jumps 15%: What Is Driving Medicenna Therapeutics Stock Higher?

What is HC Wainwright's Forecast for DWTX FY2029 Earnings?

HC Wainwright Issues Pessimistic Forecast for IPSC Earnings

HC Wainwright has lowered its Q3 2026 EPS forecast for Century Therapeutics (NASDAQ:IPSC) to a loss of $0.12 per share, down from a previous estimate of $0.11, while maintaining a "Buy" rating and a $5.00 price target. This revision follows Century Therapeutics reporting a …

Research Analysts Set Expectations for CADL Q3 Earnings

HC Wainwright has lowered its Q3 2026 EPS forecast for Candel Therapeutics (NASDAQ:CADL) to a loss of $0.35 per share, though it maintained a "Buy" rating and a $23 price target. This adjustment follows Candel Therapeutics missing its Q2 earnings consensus, reporting a loss …

What is HC Wainwright's Forecast for BCRX Q3 Earnings?

Noble Financial Has Positive Forecast for UNCY Q3 Earnings

HC Wainwright Issues Pessimistic Forecast for TRAX Earnings

Research Analysts Set Expectations for UNCY Q3 Earnings

Euro Manganese Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst